- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
Natasha B Leighl
Clin Lung Cancer. 2016 Oct 26;:
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol. 2016 Nov 19;:
Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study.
Support Care Cancer. 2016 Nov 9;
BRM Promoter Polymorphisms, Risk and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and NCIC CTG BR.24 trial.
Clin Cancer Res. 2016 Nov 8;:
Oncologist. 2016 Nov 2;:
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Genome Med. 2016 Oct 25;8(1):109
Impact of early Palliative Care on Caregivers of Patients with Advanced Cancer: Cluster Randomised Trial.
Ann Oncol. 2016 Sep 29;
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Clin Lung Cancer. 2016 Aug 8;
P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy.
J Thorac Oncol. 2016 Oct;11(10S):S241-S242
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group